Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
October 18 2017 - 7:30AM
Business Wire
- New data from more than 80 oral and
poster presentations, including research on potential predictive
and digital biomarkers
- Updates on real-world data generation
initiatives, including MS PATHS, which leverages technology in
routine care to produce real-time data, and the Big MS Data
Network, intended to provide pooled registry data from more than
140,000 people living with multiple sclerosis (MS)
- Data supporting the Phase 2
investigational molecule opicinumab (anti-LINGO-1) as a potential
therapy to repair damage to the central nervous system caused by
MS
Biogen (NASDAQ: BIIB) confirms its comprehensive approach to
tackle multiple sclerosis (MS) at the seventh Joint Meeting of the
European Committee for Treatment and Research in MS and Americas
Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS; 25 –
28 October).
“With more than 25 years of scientific leadership in MS,
Biogen’s commitment is unwavering,” said Michael Ehlers, executive
vice president, Research & Development at Biogen. “Our
expertise puts Biogen in a unique position with a comprehensive
approach including active research and clinical development on how
to repair the damage to the central nervous system from relapsing
forms of MS, a portfolio of new drug candidates that we are
advancing to the clinic, our collaboration to identify a digital
biomarker, our focus to advance understanding of the disease
through global data collection with MS PATHS, active pursuit of the
genetic origins of progressive forms of MS, and our innovation in
value-based contract pilots in the U.S.”
Key updates at ECTRIMS-ACTRIMS from Biogen include:
- The latest from the collaboration with
Verily and Brigham and Women’s Hospital whose goal is to explore
the use of digital biosensors to assess patients outside of the
clinic. Additional data on the possible utility of predictive
biomarkers to inform MS diagnosis and ongoing disease monitoring,
with the goal of assisting clinicians with their decisions on how
to treat based on the heterogeneic differences of those living with
MS, will also be presented.
- Interim reports from MS PATHS (Partners
Advancing Technology and Health Solutions), a collaboration with 10
leading MS centers in Europe and the U.S. to leverage technology
deployed in routine care to generate standardized, high-quality
data from a diverse, real-world patient population. MS PATHS
collects clinical, MRI and biologic data from all patients in
real-time, at the point of care, to better understand the disease
and ultimately improve the lives of those living with MS.
- An assessment of the Big Multiple
Sclerosis Data (BMSD) Network, comprised of five MS registries and
facilitated by Biogen. The network will merge data from large MS
registries that have collected longitudinal data on nearly 140,000
people with MS. The scale of this pooled MS data may enable greater
understanding of MS and its impact.
- A comprehensive review of the Phase 2
SYNERGY trial that identified a specific patient population for the
investigational molecule opicinumab (anti-LINGO-1) as a potential
therapy to repair damage to the central nervous system caused by
MS.
- An innovative economic model using
real-world data from the MSBase Registry with a goal to demonstrate
cost-effectiveness of treatment in highly-active MS patients. The
analysis supports value-based reimbursement initiatives linked to
patient outcomes. In July, Biogen announced four pilots for
value-based contracts with health plans across the U.S. The
contracts utilize real-world data to align price with patient
outcomes.
“With 10 centers now active and strong patient enrollment, our
MS PATHS collaboration provides a glimpse into the future of MS
care and research,” said Alfred Sandrock, M.D., Ph.D., executive
vice president and chief medical officer at Biogen. “By leveraging
technology we are able to collect a robust set of real-world data
that is unprecedented in scale and will contribute to a more
precise approach to managing patients by supporting providers in
real-time to meet the diverse needs of people living with MS.”
Highlights of Biogen’s more than 80 platform and poster
presentations:
Opicinumab
- Predictors of an Opicinumab Treatment
Effect and Identification of an Efficacy Subpopulation: A Post Hoc
Analysis of the SYNERGY Study – Poster P718 – Thursday, 26 October,
15:30-17:00 CET
- Overall Response Score: A Novel
Disability Endpoint That Allows for the Integrated Assessment of
Improvement and Worsening Over Time in Patients with MS – Poster
P777 – Thursday, 26 October, 15:30-17:00 CET
MS Franchise
- Temporal Variability Profile of Serum
Neurofilament Light Levels in Multiple Sclerosis Patients –
Platform 102 – Thursday, 26 October, 11:37–11:49 CET
- Biosensor Measures in Clinic and
Free-living Settings Correlate with Multiple Sclerosis Disease
Severity – Platform 191 – Friday, 27 October, 09:15-09:27 CET
- Big Multiple Sclerosis Data Network:
Data Sharing Among Five Large MS Registries – Poster P738 –
Thursday, 26 October, 15:30-17:00 CET
- The Multiple Sclerosis Partners
Advancing Technology and Health Solutions (MS PATHS) Patient Cohort
– Poster P336 – Thursday, 26 October, 15:30-17:00 CET
- Comparison of Case-mix in Multiple
Sclerosis Patients Participating in Randomized Control Trials,
Prospective Observational Studies, and Multiple Sclerosis Partners
Advancing Technology and Health Solutions (MS PATHS) – Poster P351
– Thursday, 26 October, 15:30-17:00 CET
- A Cost-effectiveness Analysis Using
Real-world Data from the MSBase Registry: Comparing Natalizumab to
Fingolimod in Patients with Inadequate Response to Disease
Modifying Therapies in Relapsing-remitting Multiple Sclerosis in
Scotland – Poster P700 – Thursday, 26 October, 15:30-17:00 CET
About BiogenAt Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one
of the world’s first global biotechnology companies by Charles
Weissman and Nobel Prize winners Walter Gilbert and Phillip
Sharp, today Biogen has the leading portfolio of medicines
to treat multiple sclerosis; has introduced the first and only
approved treatment for spinal muscular atrophy; and is focused on
advancing neuroscience research programs in Alzheimer’s disease and
dementia, neuroimmunology, movement disorders, neuromuscular
disorders, pain, ophthalmology, neuropsychiatry, and acute
neurology. Biogen also manufactures and commercializes biosimilars
of advanced biologics. We routinely post information that may be
important to investors on our website at www.biogen.com. To
learn more, please visit www.biogen.com and follow us on social
media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, including statements relating to the
potential impact of our programs, development and potential
benefits, safety and efficacy of investigational drugs, including
opicinumab, results of certain clinical studies and real-world
data. These statements may be identified by words such as “aim,”
“believe,” “except,” “may,” “plan,” “potential,” “will” and similar
expressions, and are based on our current beliefs and expectations.
You should not place undue reliance on these statements or the
scientific data presented. Drug development and commercialization
involve a high degree of risk, and only a small number of research
and development programs result in commercialization of a product.
Results in early stage clinical trials may not be indicative of
full results or results from later stage or larger scale clinical
trials and do not ensure regulatory approval. Factors which could
cause actual results to differ materially from our current
expectations include the risk that we may not fully enroll our
clinical trials or enrollment will take longer than expected,
unexpected concerns may arise from additional data or analysis,
including data, analysis or results obtained during our clinical
trials, regulatory authorities may require additional information
or further studies, or may fail to approve or may delay approval of
our drug candidates, or we may encounter other unexpected hurdles
which may be impacted by, among other things, the occurrence of
adverse safety events, failure to obtain regulatory approvals in
certain jurisdictions, failure to protect intellectual property and
other proprietary rights, product liability claims, third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171018005184/en/
BiogenMEDIA CONTACT:Lindsey Smith, +1
781-464-3260public.affairs@biogen.comorINVESTOR CONTACT:Ben Strain,
+1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024